BRPI0110955B8 - derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. - Google Patents

derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.

Info

Publication number
BRPI0110955B8
BRPI0110955B8 BRPI0110955A BR0110955A BRPI0110955B8 BR PI0110955 B8 BRPI0110955 B8 BR PI0110955B8 BR PI0110955 A BRPI0110955 A BR PI0110955A BR 0110955 A BR0110955 A BR 0110955A BR PI0110955 B8 BRPI0110955 B8 BR PI0110955B8
Authority
BR
Brazil
Prior art keywords
preparation
optionally substituted
drug
fluorine atoms
manufacture
Prior art date
Application number
BRPI0110955A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0110955A (pt
BRPI0110955B1 (pt
Inventor
Wood Anthony
Luzia Christa Stammen Blanda
Anthony Price David
Perros Manoussos
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0110955A publication Critical patent/BR0110955A/pt
Publication of BRPI0110955B1 publication Critical patent/BRPI0110955B1/pt
Publication of BRPI0110955B8 publication Critical patent/BRPI0110955B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
BRPI0110955A 2000-05-26 2001-05-09 derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos. BRPI0110955B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (3)

Publication Number Publication Date
BR0110955A BR0110955A (pt) 2003-06-03
BRPI0110955B1 BRPI0110955B1 (pt) 2016-06-28
BRPI0110955B8 true BRPI0110955B8 (pt) 2021-05-25

Family

ID=26244452

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0110955A BRPI0110955B8 (pt) 2000-05-26 2001-05-09 derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.

Country Status (50)

Country Link
EP (3) EP1284974B1 (OSRAM)
JP (2) JP3693957B2 (OSRAM)
KR (2) KR100548854B1 (OSRAM)
CN (2) CN1279040C (OSRAM)
AP (1) AP1965A (OSRAM)
AR (2) AR028622A1 (OSRAM)
AT (2) ATE407134T1 (OSRAM)
AU (2) AU5248201A (OSRAM)
BG (1) BG65966B1 (OSRAM)
BR (1) BRPI0110955B8 (OSRAM)
CA (1) CA2408909C (OSRAM)
CR (1) CR10145A (OSRAM)
CU (1) CU23288B7 (OSRAM)
CY (3) CY2008006I2 (OSRAM)
CZ (1) CZ299102B6 (OSRAM)
DE (3) DE60135685D1 (OSRAM)
DK (2) DK1526134T3 (OSRAM)
DZ (1) DZ3464A1 (OSRAM)
EA (2) EA007580B1 (OSRAM)
EE (1) EE05110B1 (OSRAM)
EG (1) EG24137A (OSRAM)
ES (3) ES2215129T3 (OSRAM)
FR (1) FR08C0007I2 (OSRAM)
GE (1) GEP20063799B (OSRAM)
HR (1) HRP20020938B1 (OSRAM)
HU (1) HU225810B1 (OSRAM)
IL (2) IL152531A0 (OSRAM)
IS (1) IS2511B (OSRAM)
LT (1) LTC1284974I2 (OSRAM)
LU (1) LU91417I2 (OSRAM)
MA (1) MA26902A1 (OSRAM)
ME (1) ME00555A (OSRAM)
MX (1) MXPA02011631A (OSRAM)
MY (3) MY131019A (OSRAM)
NL (1) NL300338I2 (OSRAM)
NO (3) NO327892B1 (OSRAM)
NZ (1) NZ521477A (OSRAM)
OA (1) OA12264A (OSRAM)
PA (1) PA8517101A1 (OSRAM)
PE (1) PE20011371A1 (OSRAM)
PL (1) PL200551B1 (OSRAM)
PT (2) PT1526134E (OSRAM)
RS (2) RS50904B (OSRAM)
SI (2) SI1284974T1 (OSRAM)
SK (1) SK286129B6 (OSRAM)
TN (1) TNSN01077A1 (OSRAM)
TR (1) TR200400541T4 (OSRAM)
TW (1) TWI230160B (OSRAM)
UY (1) UY26727A1 (OSRAM)
WO (1) WO2001090106A2 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152531A0 (en) * 2000-05-26 2003-05-29 Pfizer Tropane derivatives useful in therapy
KR20040007672A (ko) * 2001-06-12 2004-01-24 에스케이 주식회사 신규한 페닐알킬디아민 및 아미드 유사체
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
JP3793200B2 (ja) * 2002-04-08 2006-07-05 ファイザー・インク Ｃｃｒ５モジュレータとしてのトロパン誘導体
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
US7589207B2 (en) 2002-12-13 2009-09-15 Smithkline Beecham Corporation Cyclohexyl compounds as CCR5 antagonists
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
CA2537185A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2005023810A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
AU2004278158B2 (en) * 2003-10-03 2009-08-13 Pfizer Inc. Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
RU2006146608A (ru) 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
BRPI0712843A2 (pt) * 2006-06-12 2012-07-31 Pfizer Prod Inc antagonista de ccr5 e seus usos
DK2057125T3 (da) 2006-08-16 2011-05-16 Hoffmann La Roche Ikke-nucleosid revers transkriptase-inhibitorer
US7932235B2 (en) 2006-11-17 2011-04-26 Concert Pharmaceuticals, Inc. Triazolyl tropane derivatives
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
EP2121676A1 (en) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
AU2009220462A1 (en) * 2008-02-29 2009-09-11 Merck Sharp & Dohme Corp. CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
WO2011011652A1 (en) * 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
AU2011234013A1 (en) 2010-04-02 2012-11-15 Phivco-1 Llc Combination therapy comprising a CCR5 antagonist, a HIV-1 protease inhibitor and a pharmacokinetic enhancer
CN106977511B (zh) * 2011-12-19 2019-04-12 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GEP19991749B (en) * 1994-04-19 1999-09-10 Neurosearch As Propane-2-Aldoxine Derivatives as Neurotransmitter Reuptake Inhibitors
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6281212B1 (en) * 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
AU2335699A (en) * 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
IL152531A0 (en) * 2000-05-26 2003-05-29 Pfizer Tropane derivatives useful in therapy

Also Published As

Publication number Publication date
LTC1284974I2 (lt) 2020-11-10
EE200200656A (et) 2004-06-15
DZ3464A1 (OSRAM) 2001-11-29
SK286129B6 (sk) 2008-04-07
HU225810B1 (en) 2007-10-29
CU23288B7 (es) 2008-06-30
CY2022009I2 (el) 2022-05-27
HK1078573A1 (en) 2006-03-17
OA12264A (en) 2003-11-10
JP3693957B2 (ja) 2005-09-14
SI1526134T1 (sl) 2008-12-31
ATE407134T1 (de) 2008-09-15
AR028622A1 (es) 2003-05-14
CN100355753C (zh) 2007-12-19
HK1090836A1 (en) 2007-01-05
MXPA02011631A (es) 2003-03-27
EG24137A (en) 2008-08-06
WO2001090106A3 (en) 2002-03-28
ME00555B (me) 2011-12-20
EA200401056A1 (ru) 2005-04-28
DK1284974T3 (da) 2004-06-07
GEP20063799B (en) 2006-04-25
FR08C0007I1 (OSRAM) 2008-04-25
TNSN01077A1 (fr) 2005-11-10
HRP20020938B1 (en) 2011-05-31
DE60102233T2 (de) 2005-01-27
EA005382B1 (ru) 2005-02-24
HRP20020938A2 (en) 2005-02-28
CA2408909A1 (en) 2001-11-29
YU82202A (sh) 2005-11-28
MY153023A (en) 2014-12-31
PE20011371A1 (es) 2002-01-18
NZ521477A (en) 2004-07-30
BG65966B1 (bg) 2010-07-30
KR20030004417A (ko) 2003-01-14
NO20025227D0 (no) 2002-10-31
EA007580B1 (ru) 2006-12-29
RS51436B (sr) 2011-04-30
DE60102233D1 (de) 2004-04-08
HK1054927A1 (en) 2003-12-19
NO2020019I1 (no) 2020-06-30
DE122008000011I1 (de) 2008-06-05
NO2010007I2 (no) 2013-09-09
IL152531A (en) 2010-05-17
CN1437599A (zh) 2003-08-20
CR10145A (es) 2008-08-19
EE05110B1 (et) 2008-12-15
TWI230160B (en) 2005-04-01
ATE260914T1 (de) 2004-03-15
CZ20023806A3 (cs) 2004-01-14
IL152531A0 (en) 2003-05-29
CN1680371A (zh) 2005-10-12
LU91417I2 (fr) 2008-04-22
AU5248201A (en) 2001-12-03
ES2311126T3 (es) 2009-02-01
MA26902A1 (fr) 2004-12-20
EP1284974B1 (en) 2004-03-03
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
RS20090438A (sr) 2010-05-07
PL200551B1 (pl) 2009-01-30
TR200400541T4 (tr) 2004-04-21
AP2002002663A0 (en) 2002-12-31
LTPA2008004I1 (lt) 2020-07-27
CN1279040C (zh) 2006-10-11
PT1526134E (pt) 2008-10-28
DK1526134T3 (da) 2008-11-17
CA2408909C (en) 2006-06-27
BR0110955A (pt) 2003-06-03
JP2003534343A (ja) 2003-11-18
SI1284974T1 (en) 2004-08-31
KR20050046743A (ko) 2005-05-18
EP1526134A2 (en) 2005-04-27
LU91417I9 (OSRAM) 2019-01-02
JP2005194283A (ja) 2005-07-21
WO2001090106A2 (en) 2001-11-29
CY2022009I1 (el) 2022-05-27
PT1284974E (pt) 2004-06-30
IS6565A (is) 2002-09-24
EP1990341B1 (en) 2013-01-23
UY26727A1 (es) 2001-12-28
KR100523501B1 (ko) 2005-10-25
NL300338I1 (nl) 2008-05-01
EA200201141A1 (ru) 2003-04-24
DE60135685D1 (de) 2008-10-16
AR060159A2 (es) 2008-05-28
MY156920A (en) 2016-04-15
ES2215129T3 (es) 2004-10-01
MY131019A (en) 2007-07-31
AU2001252482B2 (en) 2006-01-19
NO2010007I1 (no) 2010-04-08
BRPI0110955B1 (pt) 2016-06-28
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
CZ299102B6 (cs) 2008-04-23
PL359267A1 (en) 2004-08-23
EP1526134B1 (en) 2008-09-03
JP4854970B2 (ja) 2012-01-18
NL300338I2 (nl) 2008-06-02
IS2511B (is) 2009-05-15
BG107140A (bg) 2003-05-30
EP1526134A3 (en) 2006-11-29
SK16432002A3 (sk) 2004-01-08
NO327892B1 (no) 2009-10-12
ME00555A (en) 2011-12-20
HUP0302474A3 (en) 2007-05-29
CY2008006I2 (el) 2009-11-04
RS50904B (sr) 2010-08-31
EP1284974A2 (en) 2003-02-26
NO20025227L (no) 2002-10-31
AP1965A (en) 2009-03-04
FR08C0007I2 (fr) 2009-01-15
AU2001252482C1 (en) 2001-12-03
EP1990341A1 (en) 2008-11-12
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24

Similar Documents

Publication Publication Date Title
BRPI0110955B8 (pt) derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
YU61595A (sh) Nova naftilna jedinjenja, njihovi intermedijeri farmaceutske kompozicije, i postupci za dobijanje tih jedinjenja
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
SE0104334D0 (sv) Therapeutic agents
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
UY27368A1 (es) Nuevos compuestos
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
BR0212069A (pt) Agentes antidiabéticos orais
BR0010139A (pt) Heterociclos bicìclicos substituìdos, processo para seu preparo e seu uso como agentes anti-obesidade e hipocolesterolêmico
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BR0016130A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0211171A (pt) Compostos quìmicos
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
DK0414422T3 (da) 2-Oxo-1-oxa-8-azaspiro(4,5)decan-derivater, fremgangsmåder til deres fremstilling samt præparater deraf
BR0214937A (pt) Processo de preparação de derivados de equinocandina
AR029618A1 (es) Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos
BR0308807A (pt) Compostos tiazol-2-il-imina como inibidores de pde-7

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K31/4196; A61K31/46; A61P1/04; A61P1/12; A61P1/18; A61P11/00; A61P11/06; A61P11/08; A61P13/12; A61P15/00; A61P25/00; A61P25/28; A61P27/16; A61P29/00; A61P3/10; A61P31/18; A61P37/00; A61P37/06; A61P43/00; A61P9/04; C07B53/00; C07B61/00; C07C233/60; C07C233/61; C07C233/63; C07D451/04; C07D

Ipc: A61K 31/4196 (2006.01), A61K 31/46 (2006.01), A61P

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/05/2021